BENGALURU, Jan 17 (Reuters) – Indian drugmaker Eris Lifesciences Ltd (ERIS.NS) stated on Tuesday it might purchase a portfolio of dermatology manufacturers from Glenmark Pharmaceuticals Ltd (GLEN.NS) for 3.4 billion rupees ($41.63 million) to deepen its presence within the anti-fungal and anti-psoriasis segments.

The deal, by means of Eris’ dermatology centered unit, is for the acquisition of 9 manufacturers, together with Onabet, Halobate, Sorvate, and Demelan for India and Nepal, Eris said.

Glenmark said, submit divestiture of the manufacturers, it is going to additional consolidate its place within the core therapeutic areas of cardiometabolic, respiratory, dermatology, and oncology segments.

The deal for the portfolio that has an annual income base of 850 million rupees, might be financed by means of borrowings, and the transaction is anticipated to realize monetary closure very quickly, Eris stated.

Separately, Eris on Tuesday reported a consolidated internet revenue of 1.02 billion rupees in its third quarter, from 1.01 billion rupees a 12 months earlier.

($1 = 81.6740 Indian rupees)

Reporting by Yagnoseni Das in Bengaluru; Editing by Shailesh Kuber

Our Standards: The Thomson Reuters Trust Principles.